Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Legal News In Brief

Executive Summary

Mylan files suit against Pittsburgh Post-Gazette: Mylan filed a civil suit against the Pittsburgh Post-Gazette, alleging that the newspaper improperly obtained and misconstrued confidential internal documents in a series of articles about its West Virginia generic plant. "The articles mischaracterized a minor deviation from internal Mylan procedure, creating the false appearance of significant quality and regulatory issues at Mylan's Morgantown, W.Va. plant when no such issues existed," Mylan said. The suit, filed in the Circuit Court of Monongalia County, W.Va., stemmed from an initial story published in late July (1"The Pink Sheet" DAILY, July 30, 2009). In an Aug. 20 Post-Gazette article, Publisher and Editor-in-chief John Robinson Block stated that the allegations are "meritless" and that the paper plans to challenge the suit. An FDA inspection following the first published Post-Gazette piece has been closed, and the agency noted that "the firm appears to have conducted an adequate investigation." The agency said it plans no additional action

You may also be interested in...



Mylan Gets First-Ever GMP Warning Letter

FDA’s GMP warning letter to Mylan cites failure to complete a required content uniformity test for generic Imodium manufactured at Puerto Rico plant.

Merck Wins Singulair Patent Battle With Teva

A federal court rules that broad scientific presentations do not constitute prior art in this case, a finding that gives Merck three years to consider an OTC switch.

Mylan Has Strong Quarter But Huge GMP Overhang

With new execs in place, firm raises EPS guidance for 2009, just days after coming under fire for quality control allegations.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel